Eagle Pharmaceuticals appoints Christopher Krawtschuk as CFO effective Nov 11, 2024

EAGLE PHARMACEUTICALS, INC.

Christopher Krawtschuk named CFO, effective Nov 11; Steven Ratoff steps down as interim CFO, remains director.
Krawtschuk previously CFO/treasurer at bluebird bio, CFO at Jubilant Pharma, U.S. CFO at Morphosys.
Offer letter: $525k base salary, 50% target bonus, $150k signing bonus, 100k performance-vesting RSUs tied to listing and SEC filings.
Shares trade on OTC Expert Market since Oct 4; 13,023,123 shares outstanding as of Oct 30.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Steven Ratoff

Interim Chief Financial Officer

EAGLE PHARMACEUTICALS, INC.

Effective: 2024-11-11
Successor: Christopher Krawtschuk
Filed: November 12, 2024, 6:59 PM ET

In connection with Mr. Krawtschuk’s appoinment, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, Steven Ratoff, stepped down from serving in such capacities on the Effective Date and will remain as a director on the Company’s board of directors.

Appointed

Christopher Krawtschuk

Chief Financial Officer

EAGLE PHARMACEUTICALS, INC.

Effective: 2024-11-11
Filed: November 12, 2024, 6:59 PM ET

On November 8, 2024, the Board of Directors (the “Board”) of Eagle Pharmaceuticals, Inc. (the “Company”) appointed Christopher Krawtschuk to serve as the Company’s Chief Financial Officer, and designated Mr. Krawtschuk as its principal financial officer and principal accounting officer, each effective November 11, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Ratoff changed role as Interim Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..

Action: stepped down
Role: Interim Chief Financial Officer

Exact text from the filing

In connection with Mr. Krawtschuk’s appoinment, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, Steven Ratoff, stepped down from serving in such capacities on the Effective Date and will remain as a director on the Company’s board of directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Krawtschuk was appointed as Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 8, 2024, the Board of Directors (the “Board”) of Eagle Pharmaceuticals, Inc. (the “Company”) appointed Christopher Krawtschuk to serve as the Company’s Chief Financial Officer, and designated Mr. Krawtschuk as its principal financial officer and principal accounting officer, each effective November 11, 2024

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-24-116329

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.